Business Context and Reporting Period
Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, filed this Form 6-K on December 23, 2016, covering the month of December 2016. The filing primarily serves to disclose a recent capital raise transaction and incorporates by reference various legal agreements and opinions.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a transaction rather than a financial statement.
Material Changes and Transactions
- Capital Raise: On December 21, 2016, the Company entered into an Underwriting and Placement Agency Agreement with Roth Capital Partners, LLC.
- Subscription: A Subscription Agreement was executed on December 21, 2016, with EMC2 Fund Ltd.
- Securities Issued: The transaction involves the issuance of American Depositary Shares (ADSs) and warrants, as evidenced by the attached Form of Warrant.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. It includes a standard legal disclaimer stating that the Form 6-K does not constitute an offer to sell or a solicitation of an offer to buy ADSs or warrants in jurisdictions where such actions would be unlawful prior to registration.
Investor Verification Checklist
- Verify the total number of ADSs and warrants issued to EMC2 Fund Ltd. and other underwriters in the attached agreements.
- Confirm the exercise price and expiration terms of the warrants described in Exhibit 4.2.
- Review the full Underwriting and Placement Agency Agreement (Exhibit 1.1) for any lock-up provisions or underwriting discounts.
- Check subsequent filings for the actual cash proceeds received from this transaction.